Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Her2 Positive Breast Cancer Treatment Market

ID: MRFR/HC/35522-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026

HER2 Positive Breast Cancer Treatment Market Research Report By Treatment Type (Monoclonal Antibodies, Chemotherapy, Targeted Therapy, Hormonal Therapy), By Drug Class (Trastuzumab, Pertuzumab, Lapatinib, Ado-trastuzumab Emtansine), By Administration Route (Intravenous, Oral, Subcutaneous), By Stage of Cancer (Early Stage, Locally Advanced Stage, Metastatic Stage) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Her2 Positive Breast Cancer Treatment Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Type (USD Billion)
  49.     4.1.1 Monoclonal Antibodies
  50.     4.1.2 Chemotherapy
  51.     4.1.3 Targeted Therapy
  52.     4.1.4 Hormonal Therapy
  53.   4.2 Healthcare, BY Drug Class (USD Billion)
  54.     4.2.1 Trastuzumab
  55.     4.2.2 Pertuzumab
  56.     4.2.3 Lapatinib
  57.     4.2.4 Ado-trastuzumab Emtansine
  58.   4.3 Healthcare, BY Administration Route (USD Billion)
  59.     4.3.1 Intravenous
  60.     4.3.2 Oral
  61.     4.3.3 Subcutaneous
  62.   4.4 Healthcare, BY Stage of Cancer (USD Billion)
  63.     4.4.1 Early Stage
  64.     4.4.2 Locally Advanced Stage
  65.     4.4.3 Metastatic Stage
  66.   4.5 Healthcare, BY Region (USD Billion)
  67.     4.5.1 North America
  68.       4.5.1.1 US
  69.       4.5.1.2 Canada
  70.     4.5.2 Europe
  71.       4.5.2.1 Germany
  72.       4.5.2.2 UK
  73.       4.5.2.3 France
  74.       4.5.2.4 Russia
  75.       4.5.2.5 Italy
  76.       4.5.2.6 Spain
  77.       4.5.2.7 Rest of Europe
  78.     4.5.3 APAC
  79.       4.5.3.1 China
  80.       4.5.3.2 India
  81.       4.5.3.3 Japan
  82.       4.5.3.4 South Korea
  83.       4.5.3.5 Malaysia
  84.       4.5.3.6 Thailand
  85.       4.5.3.7 Indonesia
  86.       4.5.3.8 Rest of APAC
  87.     4.5.4 South America
  88.       4.5.4.1 Brazil
  89.       4.5.4.2 Mexico
  90.       4.5.4.3 Argentina
  91.       4.5.4.4 Rest of South America
  92.     4.5.5 MEA
  93.       4.5.5.1 GCC Countries
  94.       4.5.5.2 South Africa
  95.       4.5.5.3 Rest of MEA
  96. 5 SECTION V: COMPETITIVE ANALYSIS
  97.   5.1 Competitive Landscape
  98.     5.1.1 Overview
  99.     5.1.2 Competitive Analysis
  100.     5.1.3 Market share Analysis
  101.     5.1.4 Major Growth Strategy in the Healthcare
  102.     5.1.5 Competitive Benchmarking
  103.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  104.     5.1.7 Key developments and growth strategies
  105.       5.1.7.1 New Product Launch/Service Deployment
  106.       5.1.7.2 Merger & Acquisitions
  107.       5.1.7.3 Joint Ventures
  108.     5.1.8 Major Players Financial Matrix
  109.       5.1.8.1 Sales and Operating Income
  110.       5.1.8.2 Major Players R&D Expenditure. 2023
  111.   5.2 Company Profiles
  112.     5.2.1 Roche (CH)
  113.       5.2.1.1 Financial Overview
  114.       5.2.1.2 Products Offered
  115.       5.2.1.3 Key Developments
  116.       5.2.1.4 SWOT Analysis
  117.       5.2.1.5 Key Strategies
  118.     5.2.2 Pfizer (US)
  119.       5.2.2.1 Financial Overview
  120.       5.2.2.2 Products Offered
  121.       5.2.2.3 Key Developments
  122.       5.2.2.4 SWOT Analysis
  123.       5.2.2.5 Key Strategies
  124.     5.2.3 AstraZeneca (GB)
  125.       5.2.3.1 Financial Overview
  126.       5.2.3.2 Products Offered
  127.       5.2.3.3 Key Developments
  128.       5.2.3.4 SWOT Analysis
  129.       5.2.3.5 Key Strategies
  130.     5.2.4 Novartis (CH)
  131.       5.2.4.1 Financial Overview
  132.       5.2.4.2 Products Offered
  133.       5.2.4.3 Key Developments
  134.       5.2.4.4 SWOT Analysis
  135.       5.2.4.5 Key Strategies
  136.     5.2.5 Merck & Co (US)
  137.       5.2.5.1 Financial Overview
  138.       5.2.5.2 Products Offered
  139.       5.2.5.3 Key Developments
  140.       5.2.5.4 SWOT Analysis
  141.       5.2.5.5 Key Strategies
  142.     5.2.6 GSK (GB)
  143.       5.2.6.1 Financial Overview
  144.       5.2.6.2 Products Offered
  145.       5.2.6.3 Key Developments
  146.       5.2.6.4 SWOT Analysis
  147.       5.2.6.5 Key Strategies
  148.     5.2.7 Bristol-Myers Squibb (US)
  149.       5.2.7.1 Financial Overview
  150.       5.2.7.2 Products Offered
  151.       5.2.7.3 Key Developments
  152.       5.2.7.4 SWOT Analysis
  153.       5.2.7.5 Key Strategies
  154.     5.2.8 Eli Lilly (US)
  155.       5.2.8.1 Financial Overview
  156.       5.2.8.2 Products Offered
  157.       5.2.8.3 Key Developments
  158.       5.2.8.4 SWOT Analysis
  159.       5.2.8.5 Key Strategies
  160.     5.2.9 Amgen (US)
  161.       5.2.9.1 Financial Overview
  162.       5.2.9.2 Products Offered
  163.       5.2.9.3 Key Developments
  164.       5.2.9.4 SWOT Analysis
  165.       5.2.9.5 Key Strategies
  166.   5.3 Appendix
  167.     5.3.1 References
  168.     5.3.2 Related Reports
  169. 6 LIST OF FIGURES
  170.   6.1 MARKET SYNOPSIS
  171.   6.2 NORTH AMERICA MARKET ANALYSIS
  172.   6.3 US MARKET ANALYSIS BY TYPE
  173.   6.4 US MARKET ANALYSIS BY DRUG CLASS
  174.   6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
  175.   6.6 US MARKET ANALYSIS BY STAGE OF CANCER
  176.   6.7 CANADA MARKET ANALYSIS BY TYPE
  177.   6.8 CANADA MARKET ANALYSIS BY DRUG CLASS
  178.   6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  179.   6.10 CANADA MARKET ANALYSIS BY STAGE OF CANCER
  180.   6.11 EUROPE MARKET ANALYSIS
  181.   6.12 GERMANY MARKET ANALYSIS BY TYPE
  182.   6.13 GERMANY MARKET ANALYSIS BY DRUG CLASS
  183.   6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  184.   6.15 GERMANY MARKET ANALYSIS BY STAGE OF CANCER
  185.   6.16 UK MARKET ANALYSIS BY TYPE
  186.   6.17 UK MARKET ANALYSIS BY DRUG CLASS
  187.   6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
  188.   6.19 UK MARKET ANALYSIS BY STAGE OF CANCER
  189.   6.20 FRANCE MARKET ANALYSIS BY TYPE
  190.   6.21 FRANCE MARKET ANALYSIS BY DRUG CLASS
  191.   6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  192.   6.23 FRANCE MARKET ANALYSIS BY STAGE OF CANCER
  193.   6.24 RUSSIA MARKET ANALYSIS BY TYPE
  194.   6.25 RUSSIA MARKET ANALYSIS BY DRUG CLASS
  195.   6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  196.   6.27 RUSSIA MARKET ANALYSIS BY STAGE OF CANCER
  197.   6.28 ITALY MARKET ANALYSIS BY TYPE
  198.   6.29 ITALY MARKET ANALYSIS BY DRUG CLASS
  199.   6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  200.   6.31 ITALY MARKET ANALYSIS BY STAGE OF CANCER
  201.   6.32 SPAIN MARKET ANALYSIS BY TYPE
  202.   6.33 SPAIN MARKET ANALYSIS BY DRUG CLASS
  203.   6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  204.   6.35 SPAIN MARKET ANALYSIS BY STAGE OF CANCER
  205.   6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
  206.   6.37 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS
  207.   6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
  208.   6.39 REST OF EUROPE MARKET ANALYSIS BY STAGE OF CANCER
  209.   6.40 APAC MARKET ANALYSIS
  210.   6.41 CHINA MARKET ANALYSIS BY TYPE
  211.   6.42 CHINA MARKET ANALYSIS BY DRUG CLASS
  212.   6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  213.   6.44 CHINA MARKET ANALYSIS BY STAGE OF CANCER
  214.   6.45 INDIA MARKET ANALYSIS BY TYPE
  215.   6.46 INDIA MARKET ANALYSIS BY DRUG CLASS
  216.   6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  217.   6.48 INDIA MARKET ANALYSIS BY STAGE OF CANCER
  218.   6.49 JAPAN MARKET ANALYSIS BY TYPE
  219.   6.50 JAPAN MARKET ANALYSIS BY DRUG CLASS
  220.   6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
  221.   6.52 JAPAN MARKET ANALYSIS BY STAGE OF CANCER
  222.   6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
  223.   6.54 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS
  224.   6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  225.   6.56 SOUTH KOREA MARKET ANALYSIS BY STAGE OF CANCER
  226.   6.57 MALAYSIA MARKET ANALYSIS BY TYPE
  227.   6.58 MALAYSIA MARKET ANALYSIS BY DRUG CLASS
  228.   6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  229.   6.60 MALAYSIA MARKET ANALYSIS BY STAGE OF CANCER
  230.   6.61 THAILAND MARKET ANALYSIS BY TYPE
  231.   6.62 THAILAND MARKET ANALYSIS BY DRUG CLASS
  232.   6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
  233.   6.64 THAILAND MARKET ANALYSIS BY STAGE OF CANCER
  234.   6.65 INDONESIA MARKET ANALYSIS BY TYPE
  235.   6.66 INDONESIA MARKET ANALYSIS BY DRUG CLASS
  236.   6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  237.   6.68 INDONESIA MARKET ANALYSIS BY STAGE OF CANCER
  238.   6.69 REST OF APAC MARKET ANALYSIS BY TYPE
  239.   6.70 REST OF APAC MARKET ANALYSIS BY DRUG CLASS
  240.   6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
  241.   6.72 REST OF APAC MARKET ANALYSIS BY STAGE OF CANCER
  242.   6.73 SOUTH AMERICA MARKET ANALYSIS
  243.   6.74 BRAZIL MARKET ANALYSIS BY TYPE
  244.   6.75 BRAZIL MARKET ANALYSIS BY DRUG CLASS
  245.   6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
  246.   6.77 BRAZIL MARKET ANALYSIS BY STAGE OF CANCER
  247.   6.78 MEXICO MARKET ANALYSIS BY TYPE
  248.   6.79 MEXICO MARKET ANALYSIS BY DRUG CLASS
  249.   6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
  250.   6.81 MEXICO MARKET ANALYSIS BY STAGE OF CANCER
  251.   6.82 ARGENTINA MARKET ANALYSIS BY TYPE
  252.   6.83 ARGENTINA MARKET ANALYSIS BY DRUG CLASS
  253.   6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  254.   6.85 ARGENTINA MARKET ANALYSIS BY STAGE OF CANCER
  255.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
  256.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS
  257.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  258.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY STAGE OF CANCER
  259.   6.90 MEA MARKET ANALYSIS
  260.   6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
  261.   6.92 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS
  262.   6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
  263.   6.94 GCC COUNTRIES MARKET ANALYSIS BY STAGE OF CANCER
  264.   6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
  265.   6.96 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS
  266.   6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  267.   6.98 SOUTH AFRICA MARKET ANALYSIS BY STAGE OF CANCER
  268.   6.99 REST OF MEA MARKET ANALYSIS BY TYPE
  269.   6.100 REST OF MEA MARKET ANALYSIS BY DRUG CLASS
  270.   6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  271.   6.102 REST OF MEA MARKET ANALYSIS BY STAGE OF CANCER
  272.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  273.   6.104 RESEARCH PROCESS OF MRFR
  274.   6.105 DRO ANALYSIS OF HEALTHCARE
  275.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  276.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  277.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  278.   6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
  279.   6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
  280.   6.111 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE)
  281.   6.112 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion)
  282.   6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  283.   6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
  284.   6.115 HEALTHCARE, BY STAGE OF CANCER, 2024 (% SHARE)
  285.   6.116 HEALTHCARE, BY STAGE OF CANCER, 2024 TO 2035 (USD Billion)
  286.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  287. 7 LIST OF TABLES
  288.   7.1 LIST OF ASSUMPTIONS
  289.     7.1.1
  290.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  291.     7.2.1 BY TYPE, 2025-2035 (USD Billion)
  292.     7.2.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  293.     7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  294.     7.2.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  295.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  296.     7.3.1 BY TYPE, 2025-2035 (USD Billion)
  297.     7.3.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  298.     7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  299.     7.3.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  300.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  301.     7.4.1 BY TYPE, 2025-2035 (USD Billion)
  302.     7.4.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  303.     7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  304.     7.4.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  305.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  306.     7.5.1 BY TYPE, 2025-2035 (USD Billion)
  307.     7.5.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  308.     7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  309.     7.5.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  310.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  311.     7.6.1 BY TYPE, 2025-2035 (USD Billion)
  312.     7.6.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  313.     7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  314.     7.6.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  315.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  316.     7.7.1 BY TYPE, 2025-2035 (USD Billion)
  317.     7.7.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  318.     7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  319.     7.7.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  320.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  321.     7.8.1 BY TYPE, 2025-2035 (USD Billion)
  322.     7.8.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  323.     7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  324.     7.8.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  325.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  326.     7.9.1 BY TYPE, 2025-2035 (USD Billion)
  327.     7.9.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  328.     7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  329.     7.9.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  330.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  331.     7.10.1 BY TYPE, 2025-2035 (USD Billion)
  332.     7.10.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  333.     7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  334.     7.10.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  335.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  336.     7.11.1 BY TYPE, 2025-2035 (USD Billion)
  337.     7.11.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  338.     7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  339.     7.11.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  340.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  341.     7.12.1 BY TYPE, 2025-2035 (USD Billion)
  342.     7.12.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  343.     7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  344.     7.12.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  345.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  346.     7.13.1 BY TYPE, 2025-2035 (USD Billion)
  347.     7.13.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  348.     7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  349.     7.13.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  350.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  351.     7.14.1 BY TYPE, 2025-2035 (USD Billion)
  352.     7.14.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  353.     7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  354.     7.14.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  355.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  356.     7.15.1 BY TYPE, 2025-2035 (USD Billion)
  357.     7.15.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  358.     7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  359.     7.15.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  360.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  361.     7.16.1 BY TYPE, 2025-2035 (USD Billion)
  362.     7.16.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  363.     7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  364.     7.16.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  365.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  366.     7.17.1 BY TYPE, 2025-2035 (USD Billion)
  367.     7.17.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  368.     7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  369.     7.17.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  370.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  371.     7.18.1 BY TYPE, 2025-2035 (USD Billion)
  372.     7.18.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  373.     7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  374.     7.18.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  375.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  376.     7.19.1 BY TYPE, 2025-2035 (USD Billion)
  377.     7.19.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  378.     7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  379.     7.19.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  380.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  381.     7.20.1 BY TYPE, 2025-2035 (USD Billion)
  382.     7.20.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  383.     7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  384.     7.20.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  385.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  386.     7.21.1 BY TYPE, 2025-2035 (USD Billion)
  387.     7.21.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  388.     7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  389.     7.21.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  390.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  391.     7.22.1 BY TYPE, 2025-2035 (USD Billion)
  392.     7.22.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  393.     7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  394.     7.22.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  395.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  396.     7.23.1 BY TYPE, 2025-2035 (USD Billion)
  397.     7.23.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  398.     7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  399.     7.23.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  400.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  401.     7.24.1 BY TYPE, 2025-2035 (USD Billion)
  402.     7.24.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  403.     7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  404.     7.24.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  405.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  406.     7.25.1 BY TYPE, 2025-2035 (USD Billion)
  407.     7.25.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  408.     7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  409.     7.25.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  410.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  411.     7.26.1 BY TYPE, 2025-2035 (USD Billion)
  412.     7.26.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  413.     7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  414.     7.26.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  415.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  416.     7.27.1 BY TYPE, 2025-2035 (USD Billion)
  417.     7.27.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  418.     7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  419.     7.27.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  420.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  421.     7.28.1 BY TYPE, 2025-2035 (USD Billion)
  422.     7.28.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  423.     7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  424.     7.28.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  425.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  426.     7.29.1 BY TYPE, 2025-2035 (USD Billion)
  427.     7.29.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  428.     7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  429.     7.29.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  430.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  431.     7.30.1 BY TYPE, 2025-2035 (USD Billion)
  432.     7.30.2 BY DRUG CLASS, 2025-2035 (USD Billion)
  433.     7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
  434.     7.30.4 BY STAGE OF CANCER, 2025-2035 (USD Billion)
  435.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  436.     7.31.1
  437.   7.32 ACQUISITION/PARTNERSHIP
  438.     7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Monoclonal Antibodies
  • Chemotherapy
  • Targeted Therapy
  • Hormonal Therapy

Healthcare By Drug Class (USD Billion, 2025-2035)

  • Trastuzumab
  • Pertuzumab
  • Lapatinib
  • Ado-trastuzumab Emtansine

Healthcare By Administration Route (USD Billion, 2025-2035)

  • Intravenous
  • Oral
  • Subcutaneous

Healthcare By Stage of Cancer (USD Billion, 2025-2035)

  • Early Stage
  • Locally Advanced Stage
  • Metastatic Stage

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions